Everlywell Brings $249 AI Breast Cancer Risk Assessments Directly to Patients

Patients can now buy a five-year breast cancer risk assessment based on a mammogram they already had. Everlywell is offering Clairity Breast across its US platform for $249. In an October 8 STAT story, Clairity explains the choice to go directly to patients: waiting for doctors and insurers to adopt the technology would have taken too long.

A second reading of the same mammogram

Clairity Breast analyzes patterns in a standard 2D screening mammogram that are associated with future cancer risk. Those patterns can carry information even when the screening examination finds no cancer. Rather than asking whether a tumor is visible today, the software estimates the likelihood of developing breast cancer over the next five years.

The image-based approach also differs from risk questionnaires. Everlywell says reading the mammogram itself can flag risk that other tools miss, potentially helping people under 50 and those without a strong family history. That second group is important to the company’s pitch: about 85% of breast cancers occur in women with no family history, according to Everlywell. Clairity founder Dr. Connie Lehman, a Harvard Medical School radiology professor, describes the mammogram as already holding risk information that the software can interpret.

Everlywell says the model was trained on 421,499 mammograms from 27 facilities in Europe, South America and the United States. Training teaches the software to recognize image patterns from examples. A separate multicenter analysis evaluated it using 245,344 bilateral 2D screening mammograms, including more than 120,000 from 10 US screening centers.

The FDA authorized Clairity Breast in 2025, according to Everlywell, which describes it as the first authorized AI platform to predict five-year breast cancer risk using only a standard mammogram. The company says the model has been evaluated across differences in age, race and breast density, while research continues on its performance across populations and clinical settings. No risk-prediction tool performs identically for every person or population.

From an imaging center to a patient account

Before the Everlywell partnership, access was limited to selected health systems, including Beth Israel Deaconess Medical Centre in Massachusetts and Invision Sally Jobe in Colorado. The US rollout changes where patients can request an assessment, rather than requiring their imaging center to offer it.

Everlywell’s consumer workflow uses an existing image, with the company handling retrieval and delivering provider-reviewed results. Its published requirements and delivery steps are:

• A compatible screening mammogram from the past 12 months is required. Not every existing mammogram will qualify.
• Everlywell says it can work with the imaging center to retrieve the image. If it cannot be used, the customer receives a full refund.
• Provider-reviewed results arrive in the patient’s My Everly account, alongside guideline-based information to discuss with their healthcare provider.

The score still needs a care decision

A higher score does not mean someone has cancer, and a lower score does not guarantee they will avoid it. Everlywell says regular mammograms and ongoing clinical care remain essential. The intended use is to inform a conversation about screening and risk reduction, not to let the number dictate care on its own.

There is a potential clinical path for acting on the result. Everlywell says 2026 National Comprehensive Cancer Network guidance allows people aged 35 and older with an image-based five-year invasive breast cancer risk of at least 1.7% to be considered for enhanced screening and risk-reduction strategies. Those options can include supplemental breast MRI.

But predicting risk and improving health are separate tests. Everlywell acknowledges that researchers are still studying whether changing screening based on these predictions improves patient outcomes. Direct access gives patients another source of information; the benefit of using it to change their care remains an open research question.